Related Experiment Video
Updated: Oct 16, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion
Domenico G Della Rocca1, Michele Magnocavallo2, Luigi Di Biase3
1Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.
Insights
Half-dose direct oral anticoagulation (hdDOAC) is more effective than standard antithrombotic therapy (SAT) after Watchman implantation. This strategy significantly reduces device-related thrombosis (DRT) and bleeding events, improving patient outcomes.
Area of Science:
- Cardiology
- Thrombosis Research
- Medical Device Innovation
Background:
- Lack of consensus on optimal antithrombotic strategies post-left atrial appendage closure.
- Device-related thrombosis (DRT) is a significant concern after Watchman implantation.
- Need for effective strategies to prevent thromboembolic and bleeding events.
Purpose of the Study:
- To compare the long-term efficacy of standard antithrombotic strategy (SAT) versus half-dose direct oral anticoagulation (hdDOAC) after Watchman implantation.
- To evaluate the prevention of device-related thrombosis (DRT), thromboembolic (TE), and bleeding events.
- To determine the optimal antithrombotic approach for patients undergoing left atrial appendage closure.
Main Methods:
- Prospective evaluation of 555 patients post-Watchman implantation.
- Patients received either SAT (n=357) or hdDOAC (n=198).
- Primary composite endpoint: DRT, TE events, and major bleeding. Median follow-up: 13 months.
Main Results:
- Device-related thrombosis (DRT) occurred in 2.1% of patients (3.4% in SAT vs. 0.0% in hdDOAC; P=0.009).
- Half-dose DOAC significantly reduced major bleeding risk (0.5% vs. 3.9%; P=0.018).
- The composite endpoint occurred in 1.0% of hdDOAC patients vs. 9.5% of SAT patients (HR: 9.8; P=0.002).
Conclusions:
- Long-term hdDOAC significantly reduces the composite endpoint of DRT, TE, and major bleeding events.
- Half-dose DOAC is a superior antithrombotic strategy compared to SAT after Watchman implantation.
- This finding supports a revised approach to antithrombotic therapy in this patient population.
Objectives:
This study evaluated the long-term efficacy of a standard antithrombotic strategy versus half-dose direct oral anticoagulation (DOAC) after Watchman implantation.
Background:
No consensus currently exists on the selection of the most effective antithrombotic strategy to prevent device-related thrombosis (DRT) in patients undergoing endocardial left atrial appendage closure.
Methods:
After successful left atrial appendage closure, consecutive patients were prescribed a standard antithrombotic strategy (SAT) or long-term half-dose DOAC (hdDOAC). The primary composite endpoint was DRT and thromboembolic (TE) and bleeding events.
Results:
Overall, 555 patients (mean age 75 ± 8 years, 63% male; median CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category] score 4 [interquartile range (IQR): 3-6]; median HAS-BLED [hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol] score 3 [IQR: 2-4]) were included. Patients were categorized into 2 groups (SAT: n = 357 vs hdDOAC: n = 198). Baseline clinical characteristics were similar between groups. The median follow-up duration was 13 months (IQR: 12-15 months). DRT occurred in 12 (2.1%) patients, all in the SAT group (3.4% vs 0.0%; log-rank P = 0.009). The risk of nonprocedural major bleeding was significantly more favorable in the hdDOAC group (0.5% vs. 3.9%; log-rank P = 0.018). The rate of the primary composite endpoint of DRT and TE and major bleeding events was 9.5% in SAT patients and 1.0% in hdDOAC patients (HR: 9.8; 95% CI: 2.3-40.7; P = 0.002).
Conclusions:
After successful Watchman implantation, long-term half-dose DOAC significantly reduced the risk of the composite endpoint of DRT and TE and major bleeding events compared with a standard, antiplatelet-based, antithrombotic therapy.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins